BioSpace News Archive

CareDx, Inc. announced that on December 20, 2019, Magistrate Judge Christopher Burke issued a report recommending that the U.S. District Court for the District of Delaware reject Natera Inc.’s motion to dismiss CareDx’s false advertising complaint.

The Antengene board announced the appointment of Mr. Mark J. Alles as an independent director of the company, effective January 2, 2020. Mr. Alles is the former Chairman and Chief Executive Officer of Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company.

BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology, announced that management will provide a corporate update at the 2020 Biotech Showcase in San Francisco, California.

Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda’s President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 9:30am PST / 12:30pm EST.

Sites now have access to a free eRegulatory application to simplify regulatory compliance and speed study execution

Qualifying Teams Hail From 19 Countries

Adagene, Inc., a clinical-stage, leading-edge oncology immunotherapy company driven by a powerful antibody discovery and engineering platform, today announced the completion of a $69 million Series D financing, including $50 million from lead investor General Atlantic.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.